Who is sponsoring NCT05368311?

NCT05368311 is sponsored by Clinica Universidad de Navarra, Universidad de Navarra.

What drugs are being tested in NCT05368311?

Interventions in NCT05368311: Dietary recommendations including protein enriched bars, Dietary recommendations without protein enriched bars.

What condition does NCT05368311 study?

NCT05368311 studies Obesity, Weight Loss, Protein.

Is NCT05368311 still recruiting?

NCT05368311 is currently completed. Last updated 12 May 2023.

Last reviewed 2023-05-12 · How we verify

NCT05368311: COLABOCO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of a Protein Intake on Weight Loss of Overweight/Obese Adults

Completed NA Last updated 12 May 2023

What this trial tests

NA trial testing Dietary recommendations including protein enriched bars in Obesity in 64 participants. Completed in 30 August 2022.

Timeline

13 January 2022

Primary endpoint
24 June 2022

30 August 2022

Quick facts

Lead sponsor	Clinica Universidad de Navarra, Universidad de Navarra
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	64
Start date	13 January 2022
Primary completion	24 June 2022
Estimated completion	30 August 2022
Sites	1 location across Spain

Drugs / interventions tested

Dietary recommendations including protein enriched bars
Dietary recommendations without protein enriched bars

Conditions studied

Obesity — all drugs for Obesity →
Weight Loss — all drugs for Weight Loss →
Protein — all drugs for Protein →

Sponsor

Clinica Universidad de Navarra, Universidad de Navarra

Who can join

Adults 20 to 65, any sex, with Obesity or Weight Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Obesity is considered the epidemic of the 21st century. Obesity is a multifactorial disease and the most important risk factors are poor diet and sedentary lifestyle. An excessive body weight contributes to increase the risk of suffering from other diseases and mortality rates. Therefore, the prevention and control of excessive body weight as well as its comorbidities are essential. In this sense, the principal strategy to treat obesity is to improve dietary habits and increase physical activity. However, the rate of obesity continues rising. In order to deal with this problem, new strategies to combat obesity are being investigated, such as the investigation of new bioactive compounds with satiating capacity that can be included in healthy dietary patterns to improve adherence to dietary treatments. Considering this background, the main objective of this research is to assess the effect of daily consumption of protein rich bars accompanied by healthy dietary recommendations on weight loss of overweight/obese adult men and women.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Anti-Obesity Effects of a Collagen with Low Digestibility and High Swelling Capacity: A Human Randomized Control Trial.
López-Yoldi M, Riezu-Boj JI, Abete I, Ibero-Baraibar I, et al · · 2024 · cited 5× · PMID 39458544 · DOI 10.3390/nu16203550

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Clinica Universidad de Navarra, Universidad de Navarra trials

Trials by the same sponsor.

NCT07370571 — NO AXILLARY SURGERY IN EARLY BREAST CANCER (OXIGENATE) · not yet recruiting
NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting
NCT07447440 — Role of Pro-Resolving Lipid Mediators in Obesity-Associated Diseases · recruiting
NCT07191210 — Co-Designed Comprehensive Transition Programme for First-Line Nurse Managers · NA · not yet recruiting
NCT07132060 — MRI-guided Dose Intensification Program Locally Advanced Pancreatic Cancer · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05368311 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Clinica Universidad de Navarra, Universidad de Navarra
Last refreshed: 12 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05368311.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing